Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Bram L. T. Ramaekers; Robert F. Wolff; Xavier Pouwels; Marije Oosterhoff; Anoukh Van Giessen; Gill Worthy; Caro Noake; Nigel Armstrong; Jos Kleijnen; Manuela A. Joore

doi:10.1007/s40273-018-0629-2

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Bram L. T. Ramaekers, Robert F. Wolff, Xavier Pouwels, Marije Oosterhoff, Anoukh Van Giessen, Gill Worthy, Caro Noake, Nigel Armstrong, Jos Kleijnen, Manuela A. Joore

Research output: Contribution to journal › Review article › Academic › peer-review

Original language	English
Pages (from-to)	917-927
Number of pages	11
Journal	Pharmacoeconomics
Volume	36
Issue number	8
DOIs	https://doi.org/10.1007/s40273-018-0629-2
Publication status	Published - 1 Aug 2018

Cite this

Ramaekers, B. L. T., Wolff, R. F., Pouwels, X., Oosterhoff, M., Van Giessen, A., Worthy, G., Noake, C., Armstrong, N., Kleijnen, J., & Joore, M. A. (2018). Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 36(8), 917-927. https://doi.org/10.1007/s40273-018-0629-2

Ramaekers, Bram L. T. ; Wolff, Robert F. ; Pouwels, Xavier ; Oosterhoff, Marije ; Van Giessen, Anoukh ; Worthy, Gill ; Noake, Caro ; Armstrong, Nigel ; Kleijnen, Jos ; Joore, Manuela A. / Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. In: Pharmacoeconomics. 2018 ; Vol. 36, No. 8. pp. 917-927.

@article{6ab389ced1f14b748f36081fcbe0323c,

title = "Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",

author = "Ramaekers, {Bram L. T.} and Wolff, {Robert F.} and Xavier Pouwels and Marije Oosterhoff and {Van Giessen}, Anoukh and Gill Worthy and Caro Noake and Nigel Armstrong and Jos Kleijnen and Joore, {Manuela A.}",

year = "2018",

month = aug

day = "1",

doi = "10.1007/s40273-018-0629-2",

language = "English",

volume = "36",

pages = "917--927",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "8",

}

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Ramaekers, Bram L. T.; Wolff, Robert F.; Pouwels, Xavier ; Oosterhoff, Marije; Van Giessen, Anoukh; Worthy, Gill; Noake, Caro; Armstrong, Nigel; Kleijnen, Jos ; Joore, Manuela A.

In: Pharmacoeconomics, Vol. 36, No. 8, 01.08.2018, p. 917-927.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Ramaekers, Bram L. T.

AU - Wolff, Robert F.

AU - Pouwels, Xavier

AU - Oosterhoff, Marije

AU - Van Giessen, Anoukh

AU - Worthy, Gill

AU - Noake, Caro

AU - Armstrong, Nigel

AU - Kleijnen, Jos

AU - Joore, Manuela A.

PY - 2018/8/1

Y1 - 2018/8/1

U2 - 10.1007/s40273-018-0629-2

DO - 10.1007/s40273-018-0629-2

M3 - Review article

VL - 36

SP - 917

EP - 927

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 8

ER -

Access to Document

10.1007/s40273-018-0629-2

https://link.springer.com/content/pdf/10.1007%2Fs40273-018-0629-2.pdf